How Yale researchers helped create the ketamine industry — and their own psychedelics startup.
<p>The clinical trial that set the stage for today’s fast-growing ketamine industry runs just three pages long and involved only eight patients. It was published, not in the <a href="https://www.nejm.org/" rel="noopener ugc nofollow" target="_blank">New England Journal of Medicine </a>or <a href="https://www.thelancet.com/" rel="noopener ugc nofollow" target="_blank">The Lancet</a>, but in a specialized journal called <a href="https://www.biologicalpsychiatryjournal.com/" rel="noopener ugc nofollow" target="_blank">Biological Psychiatry</a>.</p>
<p>Psychiatrists at the Yale School of Medicine did the research. They were seeking to understand the basic biology of depression, and in particular the role of glutamate, a chemical that carries electrical impulses in the brain. Knowing that ketamine, an anesthetic, triggers glutamate production, they gave ketamine to patients with major depression.</p>
<p><a href="https://medium.com/the-psychedelic-renaissance/how-yale-researchers-helped-create-the-ketamine-industry-and-their-own-psychedelics-startup-2cf0847c5522"><strong>Click Here</strong></a></p>